rs63749885 — PSEN1 H163Y

PSEN1 H163Y — A Founding Familial Alzheimer's Mutation

PSEN1¹¹ PSEN1
Presenilin-1: the catalytic subunit of the gamma-secretase complex, a four-protein intramembrane protease complex that cleaves the amyloid precursor protein (APP) and over 100 other substrates is the most frequently mutated gene in familial early-onset Alzheimer's disease. More than 300 pathogenic mutations have been identified; the H163Y substitution is among the best-characterised, having been tracked in a Swedish family for over three decades. Carriers typically develop Alzheimer's disease in their late forties to late fifties — decades before the typical sporadic onset — driven by an altered balance of amyloid-beta peptide species that accelerates plaque formation.

The Mechanism

Gamma-secretase²² Gamma-secretase
A heterotetramer containing presenilin-1 (catalytic), nicastrin, APH-1, and PEN-2, responsible for the final intramembrane cleavage of the amyloid precursor protein. The cleavage site determines whether the shorter, benign Aβ40 or the longer, aggregation-prone Aβ42 is produced normally trims APP through a processive carboxypeptidase mechanism: a long initial Aβ fragment is iteratively shortened before release. Wild-type gamma-secretase preferentially releases Aβ40 as the predominant product, with Aβ42 comprising only ~10% of total Aβ.

The H163Y substitution (c.487C>T; histidine to tyrosine at codon 163) lies within a conserved transmembrane domain critical for coordinating the two catalytic aspartate residues. Fernandez et al. 2014³³ Fernandez et al. 2014
FAD PSEN1 mutations dramatically reduce the carboxypeptidase trimming activity of gamma-secretase, meaning longer Aβ precursors escape without being shortened to Aβ40 — driving up the Aβ42/Aβ40 ratio. J Biol Chem, 2014 demonstrated that this impaired trimming is the primary mechanism by which H163Y and related mutations elevate the Aβ42/Aβ40 ratio. Xia et al. 2015⁴⁴ Xia et al. 2015
PSEN1 knockin mice show loss of gamma-secretase activity, elevated Aβ42/Aβ40, and 22-32% cortical neurodegeneration — supporting a loss-of-function model for FAD pathogenesis. Neuron, 2015 established that the net effect is paradoxical: total Aβ production may fall, yet the shift in species composition accelerates plaque deposition and neurodegeneration.

Downstream consequences in presymptomatic H163Y carriers include decreased plasma Aβ1-38 levels, an altered Aβ1-42/Aβ1-40 ratio trajectory with advancing age, and cortical glucose hypometabolism detectable by PET in the thalamus years before cognitive symptoms appear.

The Evidence

Sherrington et al. 1995⁵⁵ Sherrington et al. 1995
Cloning of the PSEN1 gene on chromosome 14q24.3 and identification of five early-onset FAD mutations in multi-ethnic families including the Swedish H163Y lineage. Nature, 1995 established the causal role of PSEN1 mutations in a subset of aggressive early-onset familial Alzheimer's disease. The H163Y variant has since been classified as Pathogenic in ClinVar (VCV000018130.2) and assigned OMIM allelic variant 104311.0008, with autopsy-confirmed Alzheimer's neuropathology in at least one carrier and documented amyloid burden on PiB-PET in presymptomatic mutation carriers.

Thordardottir et al. 2018⁶⁶ Thordardottir et al. 2018
22-year longitudinal follow-up of two H163Y carrier brothers; average age of symptom onset 51 ± 7 years; one brother remained cognitively intact at age 65 without biomarker evidence of Alzheimer pathology, demonstrating incomplete penetrance. Alzheimers Res Ther, 2018 documented an important nuance: while H163Y is highly penetrant, other genetic, epigenetic, and environmental modifiers can substantially delay or potentially prevent phenotypic expression.

Almkvist et al. 2017⁷⁷ Almkvist et al. 2017
In five autosomal-dominant AD families including PSEN1 H163Y carriers (n=35 carriers, n=44 non-carriers), cognitive divergence began ~10 years before expected clinical onset in episodic memory, executive function, and visuospatial domains. J Int Neuropsychol Soc, 2017 and Johansson et al. 2023⁸⁸ Johansson et al. 2023
Plasma GFAP rises ~10 years before expected onset, followed by p-tau181 and NfL closer to onset; 33 autosomal-dominant AD carriers across mutation types including H163Y. Brain, 2023 together delineate a long presymptomatic window during which biomarker changes accumulate while cognition remains preserved — the most actionable window for intervention.

Practical Actions

For individuals who carry one H163Y allele: the most important step is engaging with a specialist Alzheimer's genetics clinic for longitudinal biomarker monitoring and access to clinical trials. Emerging disease-modifying therapies targeting amyloid (anti-amyloid immunotherapy, gamma-secretase modulators) are now enrolling presymptomatic autosomal-dominant AD mutation carriers, and the benefit-risk profile of these interventions in mutation carriers is categorically different from sporadic late-onset disease. Genetic counselling for first-degree relatives is essential given the 50% per-child inheritance risk.

Pre-symptomatic biomarker monitoring — plasma Aβ42/Aβ40 ratio, GFAP, p-tau181, and NfL — can characterise stage of the pathophysiological cascade and guide trial eligibility and timing decisions. The Dominantly Inherited Alzheimer Network (DIAN) and other registries maintain observational and intervention platforms specifically for autosomal-dominant AD mutation carriers.

Interactions

APOE ε4 (rs429358) modifies age of onset in autosomal-dominant AD families: APOE4 co-carriers tend to have earlier symptom onset and faster cognitive decline than non-APOE4 carriers, while APOE2 may confer partial protection. Whether APOE genotype substantially modifies penetrance of H163Y specifically remains under investigation. Other PSEN1 mutations (including M146V, rs63750066, and I143T) follow the same gamma-secretase loss-of-function mechanism and share the clinical phenotype of early-onset autosomal dominant Alzheimer's disease.